SRX246   Click here for help

GtoPdb Ligand ID: 12262

Synonyms: compound 50 [PMID: 17234419] [3] | SRX 246 | SRX-246
Compound class: Synthetic organic
Comment: SRX246 is an orally bioavailable, selective vasopressin V1A receptor antagonist [3]. Structurally it is a β-lactam derivative with an azetidone ring as its core pharmacophore. In rat studies it is able to cross the blood-brain barrier [2]. In humans SRX246 blocks the actions of intranasal AVP on aggression/fear circuits (in a MRI study) [5].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 10
Hydrogen bond donors 1
Rotatable bonds 15
Topological polar surface area 102.5
Molecular weight 731.4
XLogP 6.04
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES O=C([C@H](N1C(=O)[C@H]([C@H]1/C=C/c1ccccc1)N1C(=O)OC[C@@H]1c1ccccc1)CC(=O)N1CCC(CC1)CCN1CCCCC1)N[C@H](c1ccccc1)C
Isomeric SMILES C[C@H](NC(=O)[C@@H](CC(=O)N1CCC(CCN2CCCCC2)CC1)N1[C@H](/C=C/c2ccccc2)[C@H](N2[C@H](COC2=O)c2ccccc2)C1=O)c1ccccc1
InChI InChI=1S/C44H53N5O5/c1-32(35-16-8-3-9-17-35)45-42(51)38(30-40(50)47-28-23-34(24-29-47)22-27-46-25-12-5-13-26-46)48-37(21-20-33-14-6-2-7-15-33)41(43(48)52)49-39(31-54-44(49)53)36-18-10-4-11-19-36/h2-4,6-11,14-21,32,34,37-39,41H,5,12-13,22-31H2,1H3,(H,45,51)/b21-20+/t32-,37+,38+,39+,41-/m0/s1
InChI Key HKPLAUMYFHPXIC-KRESLXGLSA-N
No information available.
Summary of Clinical Use Click here for help
SRX246 was advanced as a clinical lead for a number of neurological conditions.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02922166 Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans Phase 1 Interventional Azevan Pharmaceuticals
NCT02733614 Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD Phase 2 Interventional Azevan Pharmaceuticals
NCT02055638 Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder Phase 1/Phase 2 Interventional Azevan Pharmaceuticals
NCT03036397 Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans Phase 1 Interventional Azevan Pharmaceuticals 4
NCT02507284 Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease Phase 2 Interventional Azevan Pharmaceuticals 1,6